Abstract
GINS subunit complex 4 (GINS4) is fundamental to DNA replication and G1/S phase transition of the cell cycle in eukaryotes. Further, recent studies implied that GINS4 can mediate the progression of several tumors, but its mechanism in lung adenocarcinoma (LUAD) is not clarified. Therefore, the role of GINS4 in LUAD was explored. miR-133a-3p and GINS4 mRNA expression were tested through qRT-PCR. Protein levels of the two genes were assayed by Western blot. Their targeting relationship was predicted and verified by bioinformatics prediction and dual-luciferase analysis. The functions of miR-133a-3p and GINS4 in LUAD were evaluated by Transwell, wound healing, CCK-8, and flow cytometry assays. MTT assay and caspase-3 activity detection were utilized to measure the regulation of miR-133a-3p/GINS4 in the cisplatin sensitivity of LUAD cells. The results showed that GINS4 was highly expressed in LUAD cells (p < 0.05). miR-133a-3p, the upstream gene of GINS4 in LUAD, negatively mediated GINS4 expression. Moreover, overexpressing GINS4 enhanced the proliferative, migratory, and invasive abilities of LUAD cells and inhibited cell apoptosis and the sensitivity to cisplatin, while overexpressing miR-133a-3p caused the contrary results. However, the promoting effects of GINS4 overexpression on LUAD could be offset by miR-133a-3p overexpression. miR-133a-3p could regulate malignant behaviors and cisplatin sensitivity of LUAD cells through negatively regulating GINS4. In conclusion, our findings demonstrated that GINS4 was overexpressed in LUAD and promoted the malignant behavior of LUAD cells. Moreover, miR-133a-3p could negatively regulate GINS4, thereby suppressing the malignant progression and increasing the cisplatin sensitivity of LUAD.
Journal Section:
Tissue Engineering – Regenerative Medicine / Research Article
References
1.
Bu
F
, Zhu
X
, Yi
X
, Luo
C
, Lin
K
, Zhu
J
, et al. Expression profile of GINS complex predicts the prognosis of pancreatic cancer patients
. Onco Targets Ther
. 2020
;13
:11433
–44
.2.
Chang
A
. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
. Lung Cancer
. 2011
;71
(1
):3
–10
.3.
Czarnomysy
R
, Surazynski
A
, Muszynska
A
, Gornowicz
A
, Bielawska
A
, Bielawski
K
. A novel series of pyrazole-platinum(II) complexes as potential anti-cancer agents that induce cell cycle arrest and apoptosis in breast cancer cells
. J Enzyme Inhib Med Chem
. 2018
;33
(1
):1006
–23
.4.
Denisenko
TV
, Budkevich
IN
, Zhivotovsky
B
. Cell death-based treatment of lung adenocarcinoma
. Cell Death Dis
. 2018
;9
(2
):117
.5.
Di
F
, He
C
, Pu
G
, Zhang
C
. Support vector machine for lung adenocarcinoma staging through variant pathways
. G3
. 2020
;10
(7
):2423
–34
.6.
Dong
HX
, Wang
R
, Jin
XY
, Zeng
J
, Pan
J
. LncRNA DGCR5 promotes lung adenocarcinoma (LUAD) progression via inhibiting hsa-mir-22-3p
. J Cell Physiol
. 2018
;233
(5
):4126
–36
.7.
Fennell
DA
, Summers
Y
, Cadranel
J
, Benepal
T
, Christoph
DC
, Lal
R
, et al. Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer
. Cancer Treat Rev
. 2016
;44
:42
–50
.8.
Friedman
RC
, Farh
KK
, Burge
CB
, Bartel
DP
. Most mammalian mRNAs are conserved targets of microRNAs
. Genome Res
. 2009
;19
(1
):92
–105
.9.
Hokka
D
, Maniwa
Y
, Tane
S
, Nishio
W
, Yoshimura
M
, Okita
Y
, et al. Psf3 is a prognostic biomarker in lung adenocarcinoma
. Lung Cancer
. 2013
;79
(1
):77
–82
.10.
Joshi
K
, Shah
VJ
, Maddika
S
. GINS complex protein Sld5 recruits SIK1 to activate MCM helicase during DNA replication
. Cell Signal
. 2016
;28
(12
):1852
–62
.11.
Li
H
, Cao
Y
, Ma
J
, Luo
L
, Ma
B
. Expression and prognosis analysis of GINS subunits in human breast cancer
. Medicine
. 2021a
;100
(11
):e24827
.12.
Li
Q
, Wang
Y
, He
J
. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5
. J Clin Lab Anal
. 2021b
;35
(7
):e23853
.13.
Liu
B
, Liu
Z
, Wang
Y
, Lian
X
, Han
Z
, Cheng
X
, et al. Overexpression of GINS4 is associated with poor prognosis and survival in glioma patients
. Mol Med
. 2021
;27
(1
):117
.14.
Mao
Z
, Zhao
H
, Qin
Y
, Wei
J
, Sun
J
, Zhang
W
, et al. Post-transcriptional dysregulation of microRNA and alternative polyadenylation in colorectal cancer
. Front Genet
. 2020
;11
:64
.15.
Murray
N
, Turrisi
AT
3rd. A review of first-line treatment for small-cell lung cancer
. J Thorac Oncol
. 2006
;1
(3
):270
–8
.16.
Pacek
M
, Tutter
AV
, Kubota
Y
, Takisawa
H
, Walter
JC
. Localization of MCM2-7, Cdc45, and GINS to the site of DNA unwinding during eukaryotic DNA replication
. Mol Cell
. 2006
;21
(4
):581
–7
.17.
Pattanayak
B
, Garrido-Cano
I
, Adam-Artigues
A
, Tormo
E
, Pineda
B
, Cabello
P
, et al. MicroRNA-33b suppresses epithelial-mesenchymal transition repressing the MYC-EZH2 pathway in HER2+ breast carcinoma
. Front Oncol
. 2020
;10
:1661
.18.
Qu
J
, Li
M
, An
J
, Zhao
B
, Zhong
W
, Gu
Q
, et al. MicroRNA-33b inhibits lung adenocarcinoma cell growth, invasion, and epithelial-mesenchymal transition by suppressing Wnt/β-catenin/ZEB1 signaling
. Int J Oncol
. 2015
;47
(6
):2141
–52
.19.
Rong
Z
, Luo
Z
, Zhang
J
, Li
T
, Zhu
Z
, Yu
Z
, et al. GINS complex subunit 4, a prognostic biomarker and reversely mediated by Kruppel-like factor 4, promotes the growth of colorectal cancer
. Cancer Sci
. 2020
;111
(4
):1203
–17
.20.
Sarvi
S
, Mackinnon
AC
, Avlonitis
N
, Bradley
M
, Rintoul
RC
, Rassl
DM
, et al. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist
. Cancer Res
. 2014
;74
(5
):1554
–65
.21.
Scafoglio
CR
, Villegas
B
, Abdelhady
G
, Bailey
ST
, Liu
J
, Shirali
AS
, et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma
. Sci Transl Med
. 2018
;10
(467
):eaat5933
.22.
Sher
T
, Dy
GK
, Adjei
AA
. Small cell lung cancer
. Mayo Clin Proc
. 2008
;83
(3
):355
–67
.23.
Takaya
J
, Kusunoki
S
, Ishimi
Y
. Protein interaction and cellular localization of human CDC45
. J Biochem
. 2013
;153
(4
):381
–8
.24.
Takayama
Y
, Kamimura
Y
, Okawa
M
, Muramatsu
S
, Sugino
A
, Araki
H
. GINS, a novel multiprotein complex required for chromosomal DNA replication in budding yeast
. Genes Dev
. 2003
;17
(9
):1153
–65
.25.
Tane
S
, Sakai
Y
, Hokka
D
, Okuma
H
, Ogawa
H
, Tanaka
Y
, et al. Significant role of Psf3 expression in non-small-cell lung cancer
. Cancer Sci
. 2015
;106
(11
):1625
–34
.26.
Tang
Y
, Pan
J
, Huang
S
, Peng
X
, Zou
X
, Luo
Y
, et al. Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling
. J Exp Clin Cancer Res
. 2018
;37
(1
):160
.27.
Usman
M
, Okla
MK
, Asif
HM
, AbdElgayed
G
, Muccee
F
, Ghazanfar
S
, et al. A pan-cancer analysis of GINS complex subunit 4 to identify its potential role as a biomarker in multiple human cancers
. Am J Cancer Res
. 2022
;12
(3
):986
–1008
.28.
Valastyan
S
, Weinberg
RA
. Tumor metastasis: molecular insights and evolving paradigms
. Cell
. 2011
;147
(2
):275
–92
.29.
Wan
TM
, Lam
CS
, Ng
L
, Chow
AK
, Wong
SK
, Li
HS
, et al. The clinicopathological significance of miR-133a in colorectal cancer
. Dis Markers
. 2014
;2014
:1
–8
.30.
Wang
X
, Zhu
L
, Lin
X
, Huang
Y
, Lin
Z
. MiR-133a-3p inhibits the malignant progression of oesophageal cancer by targeting CDCA8
. J Biochem
. 2022
;170
(6
):689
–98
.31.
Xu
Y
, Zhang
L
, Xia
L
, Zhu
X
. MicroRNA-133a-3p suppresses malignant behavior of non-small cell lung cancer cells by negatively regulating ERBB2
. Oncol Lett
. 2021
;21
(6
):457
.32.
Yamane
K
, Naito
H
, Wakabayashi
T
, Yoshida
H
, Muramatsu
F
, Iba
T
, et al. Regulation of SLD5 gene expression by miR-370 during acute growth of cancer cells
. Sci Rep
. 2016
;6
(1
):30941
.33.
Yang
R
, Liu
N
, Chen
L
, Jiang
Y
, Shi
Y
, Mao
C
, et al. LSH interacts with and stabilizes GINS4 transcript that promotes tumourigenesis in non-small cell lung cancer
. J Exp Clin Cancer Res
. 2019
;38
(1
):280
.34.
Zhan
L
, Yang
J
, Liu
Y
, Cheng
Y
, Liu
H
. MicroRNA miR-502-5p inhibits ovarian cancer genesis by downregulation of GINS complex subunit 2
. Bioengineered
. 2021
;12
(1
):3336
–47
.35.
Zhang
Y
, Du
H
, Li
Y
, Yuan
Y
, Chen
B
, Sun
S
. Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma
. Cancer Sci
. 2020
;111
(2
):637
–46
.36.
Zhou
Y
, Jin
Z
, Wang
C
. Glycogen phosphorylase B promotes ovarian cancer progression via Wnt/β-catenin signaling and is regulated by miR-133a-3p
. Biomed Pharmacother
. 2019
;120
:109449
.37.
Zhu
Z
, Yu
Z
, Rong
Z
, Luo
Z
, Zhang
J
, Qiu
Z
, et al. The novel GINS4 axis promotes gastric cancer growth and progression by activating Rac1 and CDC42
. Theranostics
. 2019
;9
(26
):8294
–311
.© 2022 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2022
You do not currently have access to this content.
